![Peter Neubeck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Neubeck
Presidente presso Emergence Therapeutics AG
Posizioni attive di Peter Neubeck
Società | Posizione | Inizio | Fine |
---|---|---|---|
TVM Capital GmbH
![]() TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Investitore di Private Equity | 17/07/2009 | - |
Analista di Private Equity | 01/01/2008 | 17/07/2009 | |
Kurma Partners /DE/ | Investitore di Private Equity | 01/01/2019 | - |
TACALYX GmbH
![]() TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Direttore/Membro del Consiglio | - | - |
Emergence Therapeutics AG
![]() Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Presidente | - | - |
Direttore/Membro del Consiglio | 01/11/2019 | - | |
Synendos Therapeutics AG
![]() Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Direttore/Membro del Consiglio | - | - |
Kurma Partners SA
![]() Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investitore di Private Equity | - | - |
Storia della carriera di Peter Neubeck
Precedenti posizioni note di Peter Neubeck
Società | Posizione | Inizio | Fine |
---|---|---|---|
Aspireo Pharmaceuticals Ltd.
![]() Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Direttore/Membro del Consiglio | - | - |
Corporate Officer/Principal | - | - |
Formazione di Peter Neubeck
INSEAD | Masters Business Admin |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Harvard Medical School | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 6 |
Francia | 3 |
Israele | 2 |
Posizioni
Director/Board Member | 4 |
Private Equity Investor | 3 |
Doctorate Degree | 2 |
Settori
Finance | 4 |
Consumer Services | 4 |
Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 7 |
---|---|
TVM Capital GmbH
![]() TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Aspireo Pharmaceuticals Ltd.
![]() Aspireo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Aspireo Pharmaceuticals Ltd. operates as a biopharmaceutical company. It focuses on the development of of a novel somatostatin analog for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing ’s disease and diabetic retinopathy. The company’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide. Aspireo Pharmaceuticals was founded in 2010 and is headquartered in Tel Aviv, Israel. | Health Technology |
Kurma Partners /DE/ | Finance |
TACALYX GmbH
![]() TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
Emergence Therapeutics AG
![]() Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Health Technology |
Synendos Therapeutics AG
![]() Synendos Therapeutics AG Medical SpecialtiesHealth Technology Synendos Therapeutics AG develops molecules for the treatment of anxiety and stress-related disorders. The company was founded by Andrea Chicca, Simon Russell and Jürg Gertsch in April 2019 and is headquartered in Allschwil, Switzerland. | Health Technology |
Kurma Partners SA
![]() Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Finance |
- Borsa valori
- Insiders
- Peter Neubeck
- Esperienza